TP53 and acute myeloid leukemia: Preclinical studies in AML cell lines and primary AML cells show the combination of pevonedistat and belinostat to be highly synergistic, particularly in high-risk phenotypes such as p53 mutant and FLT-3-ITD positive cells [30].